Hepatitis B vaccination after living donor liver transplantation

Liver International

Volumn 27, Issue 7, 2007, Pages 977-982

  Soejima, Yuji ^a   Ikegami, Toru ^a   Taketomi, Akinobu ^a   Yoshizumi, Tomoharu ^a   Uchiyama, Hideaki ^a   Harada, Noboru ^a   Yamashita, Yoichi ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Anti HBc positive donor; Hepatitis B vaccination; Living donor liver transplantation

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; HEPTAVAX; LAMIVUDINE; PREDNISOLONE; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACTIVE IMMUNIZATION; ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; LIVER FUNCTION TEST; LIVER GRAFT; LIVER TRANSPLANTATION; LIVING DONOR; MALE; MULTIPLE CYCLE TREATMENT; PROSPECTIVE STUDY; SEROCONVERSION;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LAMIVUDINE; LIVER; LIVER TRANSPLANTATION; LIVING DONORS; MALE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547903914     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01521.x     Document Type: Article

References (30)

1. Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113: 1668-74.
2. Uemoto S, Sugiyama K, Marusawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 65: 494-9.
3. Holt D, Thomas R, Van Thiel D, Brems JJ. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002; 137: 572-5.
4. Brechot C, Kremsdorf D, Paterlini P, Thiers V. Hepatitis B virus DNA in HBsAg-negative patients. Molecular characterization and clinical implications. J Hepatol 1991; 13: S49-55.
5. Gandhoke I, Gupta S, Lal S, Khare S. Immuneresponse to recombinant hepatitis B vaccination in adults. J Commun Dis 2003; 35: 249-55.
6. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315: 209-14.
7. Gandhi RT, Wurcel A, Lee H, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: Implications for hepatitis B vaccine strategies. J Infect Dis 2005; 191: 1435-41.
8. Choy BY, Peiris JS, Chan TM, Lo SK, Lui SL, Lai KN. Immunogenicity of intradermal hepatitis B vaccination in renal transplant recipients. Am J Transplant 2002; 2: 965-9.
9. Castells L, Esteban R. Hepatitis B vaccination in liver transplant candidates. Eur J Gastroenterol Hepatol 2001; 13: 359-61.
10. Yetgin S, Tunc B, Koc A, Toksoy HB, Ceyhan M, Kanra G. Two booster dose hepatitis B virus vaccination in patients with leukemia. Leuk Res 2001; 25: 647-9.
11. Loinaz C, de Juanes JR, Gonzalez EM, et al. Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology 1997; 44: 235-8.
12. Sanchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496-501.
13. Angelico M, Di Paolo D, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35: 176-81.
14. Chang SH, Suh KS, Yi NJ, et al. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 2003; 37: 1329-34.
15. Hadler SC, Murphy BL, Schable CA, Heyward WL, Francis DP, Kane MA. Epidemiological analysis of the significance of low-positive test results for antibody to hepatitis B surface and core antigens. J Clin Microbiol 1984; 19: 521-5.
16. Lok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology 1988; 8: 766-70.
17. Lo CM, Fan ST, Liu CL, et al. Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liv Transpl 2003; 9: 827-32.
18. Chen YS, Wang CC, de Villa VH, et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002; 16: 405-9.
19. Prieto M, Gomez MD, Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liv Transpl 2001; 7: 51.
20. Marusawa H, Osaki Y, Kimura T, et al. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut 1999; 45: 284-288.
21. Manzarbeitia C, Reich DJ, Ortiz JA, Rothstein KD, Araya VR, Munoz SJ. Safe use of livers from donors with positive hepatitis B core antibody. Liv Transpl 2002; 8: 556-61.
22. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59: 230-4.
23. Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liv Transpl Surg 1997; 3: 105-11.
24. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68: 1058-61.
25. Burton JR Jr, Shaw-Stiffel TA. Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: A survey of current practice in the United States. Liv Transpl 2003; 9: 837-42.
26. Liu YL, Kao MT, Huang CC. A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis. Vaccine 2005; 23: 3957-60.
27. DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: Earlier is better. Am J Kidney Dis 2003; 42: 1184-92.
28. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993; 270: 2935-9.
29. Godkin A, Davenport M, Hill AV. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology 2005; 41: 1383-90.
30. Bienzle U, Gunther M, Neuhaus R, et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003; 38: 811-9.